Amidino Hydrazines Or Hydrazones (i.e., N-n=c-n Or N=c-n-n) Patents (Class 514/632)
-
Patent number: 10881626Abstract: Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.Type: GrantFiled: May 1, 2017Date of Patent: January 5, 2021Assignee: Pathologica LLCInventors: John McKearn, Jeremy Blitzer
-
Patent number: 10292950Abstract: Disclosed herein are compounds, pharmaceutical compositions, and methods for the treatment of diseases such as inflammation and/or pain, comprising the administration of a therapeutically effective amount of a non-steroidal, non-opioid compound having GI-/renal-/platelet-sparing activities, and wide safety margins with no appreciable inhibition of either form of cyclooxygenase.Type: GrantFiled: May 12, 2017Date of Patent: May 21, 2019Assignee: Pathologica LLCInventors: John McKearn, Jeremy Blitzer
-
Patent number: 10080728Abstract: The invention relates to medicine, namely, to the solutions used for hemostasis. The hemostatic agent, which represents a polyammonia methanediamine chloride of the general formula where: n=1-20, m=1-10, at that n×m?8. The hemostatic agent may be applied in the form of a 0.01-10% aqueous solution. An aqueous solution of the preparation can be used for impregnation of materials used for bleeding arrest, suture material, bandaging material. The hemostatic agent may be used in the composition of a retraction cord, adhesive pastes, vaginal and rectal suppositories, creams, gels, as well as used with microchips that provide slow release of the preparation. The preparation can also be used in eye drops, eye ointments, and lubricants applied to the surface of the catheter. The drug can be used in endodontic treatment, may be injected into a polymer sealer for root canal obturation, as well as locally—by means of electrophoresis.Type: GrantFiled: April 20, 2015Date of Patent: September 25, 2018Inventors: Viktor Veniaminovich Tets, Georgy Viktorovich Tets
-
Patent number: 9775818Abstract: The invention comprises methods for treating and preventing a bacterial infection in a subject, methods for preparing a medicament for use in treating and preventing a bacterial infection in a subject, and pharmaceutical and veterinary antibacterial compositions when used therein.Type: GrantFiled: November 29, 2016Date of Patent: October 3, 2017Assignee: NEOCULI PTY LTDInventors: Stephen Page, Sanjay Garg
-
Patent number: 9668988Abstract: Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.Type: GrantFiled: September 9, 2014Date of Patent: June 6, 2017Assignee: Pathologica LLCInventors: John McKearn, Jeremy Blitzer
-
Patent number: 9616035Abstract: Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease.Type: GrantFiled: October 25, 2013Date of Patent: April 11, 2017Assignee: PATHOLOGICA, LLCInventors: John McKearn, Jeremy Blitzer
-
Patent number: 9539223Abstract: The invention comprises methods for treating and preventing a bacterial infection in a subject, methods for preparing a medicament for use in treating and preventing a bacterial infection in a subject, and pharmaceutical and veterinary antibacterial compositions when used therein.Type: GrantFiled: May 1, 2014Date of Patent: January 10, 2017Assignee: NEOCULI PTY LTDInventors: Stephen Page, Sanjay Garg
-
Publication number: 20150148359Abstract: Uses of a compound of any of Formulas I-VI as a cytotoxic inhibitor of undifferentiated cells are disclosed herein, as well as pharmaceutical compositions comprising a compound of any of Formulas I-VI, and methods for identifying a lead candidate for inhibiting undifferentiated cells. Further disclosed are uses of an SCD-1 inhibitor as a cytotoxic inhibitor of undifferentiated cells.Type: ApplicationFiled: May 22, 2013Publication date: May 28, 2015Inventors: Uri Ben-David, Nissim Benvenisty, Payal Arora, Qing-Fen Gan, Ralph J. Garippa
-
Publication number: 20140377345Abstract: Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.Type: ApplicationFiled: September 9, 2014Publication date: December 25, 2014Inventors: John McKearn, Jeremy Blitzer
-
Patent number: 8912214Abstract: Described herein are Chk2-inhibitor compounds and derivatives thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions thereof.Type: GrantFiled: July 27, 2006Date of Patent: December 16, 2014Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Yves Pommier, Robert H. Shoemaker, Dominic Scudiero, Michael Currens, John Cardellina, Andrew Jobson
-
Publication number: 20140364453Abstract: A method is disclosed for the in vivo treatment of a breast cancer tumor utilizing a therapeutically effective amount of an agent that inactivates the Rac1 GTPase and results in a reduction in cancer cell invasion, reduced cancer cell motility, and reduced volume and weight of the tumor. Agents that can be used in this treatment include salubrinal, guanabenz, and combinations thereof. The agents additionally have proven useful in reducing the development of osteoclastogenesis and reducing bone metastasis.Type: ApplicationFiled: June 5, 2014Publication date: December 11, 2014Applicant: Indiana University Research and Technology CorporationInventors: Hiroki Yokota, Kazunori Hamamura
-
Patent number: 8853276Abstract: The invention relates to novel guanidine derivatives in the cinnamic series of general formula (I): The invention also relates to the process for preparing said guanidine derivatives and also to synthetic intermediates. Finally, the invention relates to the use of the guanidine derivatives for the preparation of compositions with anti-glycation properties, especially in cosmetology.Type: GrantFiled: September 6, 2011Date of Patent: October 7, 2014Assignee: Produits Chimiques Auxiliaires et de SyntheseInventors: Sylvain Rault, Jean Charles Lancelot, Peggy Suzanne, Anne-Sophie Voisin-Chiret, Regis Pecquet, Jean-Christophe Joseph
-
Publication number: 20140235562Abstract: A method of treating an ocular disorder in a subject includes administering to the subject a therapeutically effective amount of an agent that modulates at least one target in a signaling cascade associated with light induced retinal degeneration, aberrant all-trans-retinal accumulation, and/or generation of reactive oxygen species (ROS).Type: ApplicationFiled: April 25, 2014Publication date: August 21, 2014Inventors: Krzysztof Palczewski, Yu Chen
-
Publication number: 20140187643Abstract: Disclosed herein are compounds, pharmaceutical compositions, and methods for the treatment of diseases such as inflammation and/or pain, comprising the administration of a therapeutically effective amount of a non-steroidal, non-opioid compound having GI-/renal-/platelet-sparing activities, and wide safety margins with no appreciable inhibition of either form of cyclooxygenase.Type: ApplicationFiled: September 23, 2013Publication date: July 3, 2014Applicant: PATHOLOGICA LLCInventors: John McKearn, Jeremy Blitzer
-
Publication number: 20140051765Abstract: Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease.Type: ApplicationFiled: October 25, 2013Publication date: February 20, 2014Applicant: PATHOLOGICA LLCInventors: John McKearn, Jeremy Blitzer
-
Patent number: 8618091Abstract: The present invention provides a photosensitizing composition for treatment of MRSA comprising a photosensitizer and chlorhexidine and a pharmaceutically acceptable carrier. The present invention also provides a method for reducing disease causing microbes comprising: applying the composition comprising a photosensitizer, chlorhexidine at a concentration of more than about 0.01% and less than about 2% v/v, and a pharmaceutically acceptable carrier to a treatment site; and applying light to the treatment site at a wavelength absorbed by the photosensitizer so as to reduce the microbes at the treatment site.Type: GrantFiled: July 9, 2012Date of Patent: December 31, 2013Assignee: Ondine International Ltd.Inventors: Cale Street, Nicolas Loebel, Lisa Pedigo
-
Patent number: 8609734Abstract: Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease.Type: GrantFiled: July 24, 2012Date of Patent: December 17, 2013Assignee: Pathdogica, LLCInventors: John McKearn, Jeremy Blitzer
-
Publication number: 20130317113Abstract: The present invention provides methods for the regulation of osteopontin activity in a subject as well as for treating or preventing conditions associated with an increased activity of osteopontin activity in a subject.Type: ApplicationFiled: April 18, 2013Publication date: November 28, 2013Applicant: Pathologica LLCInventors: Kenneth G. Hadlock, Hope Lancero, Stephanie Yu, Hien Kim Do
-
Publication number: 20130295009Abstract: The present invention relates to the use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is H or OH; R1, R2, R3, R4 and R5 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, electron donor groups such as alkoxy having 1-5 carbon atoms or hydroxy, electron acceptor groups selected from cyano, nitro, trifluoroalkyl or amide; alkylamino, benzoyloxy, nitroxy, phenyl or sulpho; and the pharmacologically active salts thereof;Type: ApplicationFiled: March 14, 2013Publication date: November 7, 2013Inventors: Torbjorn LUNDSTEDT, Anna SKOTTNER, Elisabeth SEIFERT
-
Patent number: 8546452Abstract: The present invention relates to arylamidrazone derivatives having an antagonistic action against S1P3 receptors represented by the following formula (1) or a pharmaceutically acceptable salt thereof:Type: GrantFiled: October 11, 2006Date of Patent: October 1, 2013Assignee: TOA Eiyo Ltd.Inventors: Shin-ya Ohnuma, Takeshi Hasegawa, Tomoyuki Sada
-
Patent number: 8497306Abstract: The invention relates to pharmaceutically acceptable salts of guanylhydrazone-containing compounds, for example, Semapimod. The invention also relates to pharmaceutically acceptable compositions comprising the salts and methods for their use.Type: GrantFiled: October 31, 2007Date of Patent: July 30, 2013Assignee: Ferring B.V.Inventor: Thais M. Sielecki-Dzurdz
-
Patent number: 8410174Abstract: The present invention relates to the use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is H or OH; R1, R2, R3, R4 and R5 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, electron donor groups such as alkoxy having 1-5 carbon atoms or hydroxy, electron acceptor groups selected from cyano, nitro, trifluoroalkyl or amide; alkylamino, benzoyloxy, nitroxy, phenyl or sulpho; and the pharmacologically active salts thereof.Type: GrantFiled: March 21, 2012Date of Patent: April 2, 2013Assignee: AnaMar ABInventors: Torbjörn Lundstedt, Anna Skottner, Elisabeth Seifert
-
Patent number: 8367645Abstract: The invention relates to a composition that includes a first agent selected including an agent that possesses anti-inflammatory activity or acetaminophen, phenacetin, tramadol and the like; a second agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5-monophosphate-activated Protein kinase (AMPK) activator; a third agent that possesses or maintains serotonin activity.Type: GrantFiled: May 18, 2009Date of Patent: February 5, 2013Inventor: Chien-Hung Chen
-
Publication number: 20120289604Abstract: Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease.Type: ApplicationFiled: July 24, 2012Publication date: November 15, 2012Applicant: PATHOLOGICA LLCInventors: John McKearn, Jeremy Blitzer
-
Patent number: 8309609Abstract: The present invention relates to the use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is H or OH; R1, R2, R3, R4 and R5 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, electron donor groups such as alkoxy having 1-5 carbon atoms or hydroxy, electron acceptor groups selected from cyano, nitro, trifluoroalkyl or amide; alkylamino, benzoyloxy, nitroxy, phenyl or sulpho; and the pharmacologically active salts thereof.Type: GrantFiled: September 28, 2010Date of Patent: November 13, 2012Assignee: Anamar ABInventors: Torbjörn Lundstedt, Anna Skottner, Elisabeth Seifert
-
Publication number: 20120269891Abstract: Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.Type: ApplicationFiled: January 19, 2012Publication date: October 25, 2012Applicant: PATHOLOGICA LLCInventors: John McKearn, Jeremy Blitzer
-
Patent number: 8258186Abstract: Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease.Type: GrantFiled: July 16, 2010Date of Patent: September 4, 2012Assignee: Pathologica, LLCInventors: John McKearn, Jeremy Blitzer
-
Patent number: 8247455Abstract: The present invention relates to compounds having the formula: salts thereof; compositions comprising one or more of the compounds and/or salts thereof; methods of using; and methods of making.Type: GrantFiled: December 7, 2010Date of Patent: August 21, 2012Assignee: Ferring B.V.Inventor: Thais Sielecki-Dzurdz
-
Patent number: 8247406Abstract: The present invention provides a photosensitizing composition for treatment of MRSA comprising a photosensitizer and chlorhexidine and a pharmaceutically acceptable carrier. The present invention also provides a method for reducing disease causing microbes comprising: applying the composition comprising a photosensitizer, chlorhexidine at a concentration of more than about 0.01% and less than about 2% v/v, and a pharmaceutically acceptable carrier to a treatment site; and applying light to the treatment site at a wavelength absorbed by the photosensitizer so as to reduce the microbes at the treatment site.Type: GrantFiled: July 30, 2009Date of Patent: August 21, 2012Assignee: Ondine International Ltd.Inventors: Cale Street, Nicolas Loebel, Lisa Pedigo
-
Publication number: 20120196819Abstract: Compositions and methods for the treatment and control of various conditions in an animal which comprises administering to said animal an effective amount of a immediate release composition of about 0.5% to 50% wt/wt of active ingredient together with excipients to a total of about 100%, wherein said compositon dissolves in a relatively short period of time, e.g., 75 seconds or less, 5 seconds or less, or 3 seconds or less, upon administration to said animal.Type: ApplicationFiled: January 4, 2012Publication date: August 2, 2012Applicant: NEWMARKET PHARMACEUTICALS LLCInventors: David ROCK, Mark RIDALL
-
Publication number: 20120190751Abstract: The present invention relates to the use of benzylideneaminoguanidines for the treatment of inflammation and pain. In one preferred embodiment, the invention relates to the use of N-(2-chloro-3,4-dimethoxybenzylideneamino)guanidine for the treatment of rheumatoid arthritis.Type: ApplicationFiled: July 30, 2010Publication date: July 26, 2012Applicant: ANA-MAR ABInventors: Niklas Palmqvist, Anders Sjödin, Christina Wenglén, Christofer Flood, Lennart Lundberg, Elisabeth Seifert, Per Lek, Arne Boman
-
Publication number: 20120178820Abstract: The present invention relates to the use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is H or OH; R1, R2, R3, R4 and R5 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, electron donor groups such as alkoxy having 1-5 carbon atoms or hydroxy, electron acceptor groups selected from cyano, nitro, trifluoroalkyl or amide; alkylamino, benzoyloxy, nitroxy, phenyl or sulpho; and the pharmacologically active salts thereof.Type: ApplicationFiled: March 21, 2012Publication date: July 12, 2012Applicant: AnaMar ABInventors: Torbjörn LUNDSTEDT, Anna SKOTTNER, Elisabeth SEIFERT
-
Publication number: 20120115959Abstract: The present invention relates in general to therapeutic compositions and methods of use. In preferred embodiments, the invention relates to the field of eye health. In some embodiments, the invention relates to the prevention and treatment of macular degeneration by administering compounds disclosed herein. In some embodiments, the invention relates to compositions and methods of improving vision. The present invention includes compositions and methods that provide protection in a patient suffering from an eye disease such as age-related macular degeneration. In certain embodiments, the compositions of the present invention are administered during degeneration, and the composition includes an effective amount of an agent that increases choroidal blood flow.Type: ApplicationFiled: November 23, 2011Publication date: May 10, 2012Inventor: George C. Chiou
-
Publication number: 20120108668Abstract: The invention relates to the use of endogenous metabolites to produce a metabolic profile of a disorder or disease in a subject, e.g. an autoimmune disease, in particular rheumatoid arthritis, and the analysis of such metabolic profiles in order to find disturbances in such profiles in a subject which are caused by or correlated with the said diseases or disorders. Such disturbances can be normalised by treatment of the subject with specified compounds, particularly N-(2-chloro-3,4-dimethoxybenzylideneamino)guanidine or an aminoguanidine.Type: ApplicationFiled: March 24, 2010Publication date: May 3, 2012Inventors: Erik Torbjörn Lundstedt, Nils Johan Trygg, Jon Robert Gabrielsson, Gunilla Ekström, Nils Johan Trygg, Jon Robert Gabrielsson, Gunilla Ekström
-
Patent number: 8148429Abstract: The present invention relates to the use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is H or OH; R1, R2, R3, R4 and R5 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, electron donor groups such as alkoxy having 1-5 carbon atoms or hydroxy, electron acceptor groups selected from cyano, nitro, trifluoroalkyl or amide; alkylamino, benzoyloxy, nitroxy, phenyl or sulpho; and the pharmacologically active salts thereof.Type: GrantFiled: December 15, 2006Date of Patent: April 3, 2012Assignee: AnaMar ABInventors: Torbjörn Lundstedt, Anna Skottner, Elisabeth Seifert
-
Publication number: 20120022166Abstract: Methods for modulating macrophage proliferation in an individual afflicted with or at risk for a macrophage-associated disease are provided. The methods employ a polyamine analog, or salt or protected derivative thereof. Macrophage proliferation has been implicated in a number of serious disorders, including AIDS (HIV)-associated dementia, AIDS-associated non-Hodgkin's lymphoma, and Alzheimer's disease. The invention also provides methods for aiding diagnosis and monitoring therapy of a macrophage-associated non-HIV associated dementia, especially Alzheimer's disease. The invention also provides methods of delaying development of macrophage-associated non-HIV associated dementias, including Alzheimer's disease, which entail administration of an agent which modulates macrophage proliferation.Type: ApplicationFiled: July 25, 2011Publication date: January 26, 2012Inventor: Michael S. McGrath
-
Patent number: 8053449Abstract: Various methods of administering medication(s) that inhibit the nonenzymatic formation of glycation and dehydration condensation complexes known as advanced glycation end-products (AGEs) or modulate the advanced glycation end-product receptor (RAGE) are provided. Also, a medication releasing medical devices, wherein at least a portion of the medical device releasably includes at least one of these medication(s) are provided.Type: GrantFiled: October 2, 2006Date of Patent: November 8, 2011Assignee: Cell Viable CorporationInventor: Jill D. Fabricant
-
Patent number: 8048896Abstract: Various methods of administering medication(s) that inhibit the nonenzymatic formation of glycation and dehydration condensation complexes known as advanced glycation end-products (AGEs) or modulate the advanced glycation end-product receptor (RAGE) are provided.Type: GrantFiled: December 6, 2007Date of Patent: November 1, 2011Assignee: Cell Viable CorporationInventor: Jill D. Fabricant
-
Publication number: 20110172258Abstract: Compounds of formula (Ia): wherein R1, R2, R3, R4a, R4b, R5 and R6 are defined herein, as well as other indene derivatives are disclosed herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.Type: ApplicationFiled: September 22, 2009Publication date: July 14, 2011Applicant: AQUINOX PHARMACEUTICALS INC.Inventors: Jeffery R. Raymond, Kang Han, Yuanlin Zhou, Yuehua He, Bradley Noren, James Gee Ken Yee
-
Publication number: 20110144043Abstract: The present invention is directed to methods, kits and compositions for modulating the activity of Stat molecules (e.g., Stat1, Stat3 and Stat5). The compounds of the invention are useful for treating and/or preventing disorders characterized by Stat dysregulation, such as hyperproliferative disorders. Further, the compounds of the present invention are also useful in culturing stem cells and treating ischemic disorders.Type: ApplicationFiled: December 11, 2009Publication date: June 16, 2011Applicant: Dana-Farber Cancer InstituteInventor: David A. Frank
-
Publication number: 20110112199Abstract: Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease.Type: ApplicationFiled: July 16, 2010Publication date: May 12, 2011Applicant: PATHOLOGICA LLCInventors: John McKearn, Jeremy Blitzer
-
Publication number: 20110091418Abstract: Methods for treating viral infections using polyamine analogs, including mitoguazone (MGBG), are provided. In these methods, polyamine analogs destroy macrophages that act as viral reservoirs, facilitating the destruction of the viruses that dwell within the macrophages. Examples of viral infections that may be treated with the present methods include, but are not limited to, infections from human immunodeficiency viruses. These methods differ from previous methods of treatment using polyamine analogs, wherein the polyamine analogs were administered only as anti-tumor agents.Type: ApplicationFiled: December 21, 2010Publication date: April 21, 2011Applicant: Pathlogica, LLCInventors: Michael S. McGrath, Kenneth G. Hadlock
-
Patent number: 7879914Abstract: Methods for treating viral infections using polyamine analogs, including mitoguazone (MGBG), are provided. In these methods, polyamine analogs destroy macrophages that act as viral reservoirs, facilitating the destruction of the viruses that dwell within the macrophages. Examples of viral infections that may be treated with the present methods include, but are not limited to, infections from human immunodeficiency viruses. These methods differ from previous methods of treatment using polyamine analogs, wherein the polyamine analogs were administered only as anti-tumor agents.Type: GrantFiled: September 25, 2006Date of Patent: February 1, 2011Assignee: Pathlogica LLCInventors: Michael S. McGrath, Kenneth G. Hadlock
-
Patent number: 7863334Abstract: The present invention relates to compounds having the formula: salts thereof; compositions comprising one or more of the compounds and/or salts thereof; methods of using; and methods of making.Type: GrantFiled: September 17, 2007Date of Patent: January 4, 2011Assignee: Cytokine PharmaSciences, Inc.Inventor: Thais M. Sielecki-Dzurdz
-
Publication number: 20100285032Abstract: ERR? is expressed in bone and cartilage in vivo and osteoblastic and chondrocytic cells in vitro. ERR? is a transcriptional activator of an osteoblast-associated osteopontin (OPN) and chondrocyte-associated (Sox9) gene in osteoblasts and chondrocytes respectively. Knockdown of ERR? expression by antisense oligonucleotide strategies in osteoblastic cell cultures reduces alkaline phosphatase activity. Together these findings indicate that ERR? is expressed in and plays a functional role in bone and cartilage. The results also indicate that agonists and antagonists of ERR? may be useful as therapeutic agents in a wide variety of diseases affecting bones and joints.Type: ApplicationFiled: June 9, 2008Publication date: November 11, 2010Inventors: Jane E. Aubin, Marco Cardelli, Ralph A. Zirngibl
-
Publication number: 20100196286Abstract: Methods, devices and kits for treating sleep disorders, anxiety disorders, and developmental disorders, and/or for inducing an arousable state of sedation in a subject, are described. For example, inhalation methods, devices and kits for treating insomnia, anxiety and/or ADHD using one or more ?2-adrenergic agonists such as dexmedetomidine or clonidine are described.Type: ApplicationFiled: December 1, 2009Publication date: August 5, 2010Inventors: Thomas A. ARMER, Robert O. Cook, Terry Alfredson, Anthony Sun
-
Publication number: 20100179225Abstract: A method is provided, comprising administering at least one guanylhydrazone or salt thereof or a combination thereof to a subject to prevent or ameliorate in said subject at least one of postoperative intestinal inflammation, postoperative ileus, ischemia reperfusion injury, or a combination thereof.Type: ApplicationFiled: September 15, 2009Publication date: July 15, 2010Applicants: CYTOKINE PHARMASCIENCES, INC., RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONNInventors: Jörg KALFF, Sven Wehner, Nico Schäfer, Thais M. Sielecki-Dzurdz
-
Publication number: 20100160332Abstract: The adrenergic receptors or adrenoceptors are a family of G-protein coupled receptors split into ? and ? subclasses. The adrenoceptors have important roles in regulating a myriad of physiological conditions and their malfunction has been implicated in the pathophysiology of a number of diseases. Disclosed herein are a series of novel compounds which are ligands of the alpha2-adrenoceptor (?2-ARs) subclass of adrenergic receptors. The invention also provides for pharmaceutical compositions comprising the novel compounds. The compounds are suitable for use in the manufacture of medicaments for the treatment of ?2-ARs associated disorders, such as depression and schizophrenia.Type: ApplicationFiled: December 22, 2009Publication date: June 24, 2010Applicant: The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen ElizabeInventors: Maria Isabel Rozas Hernando, Fernando Rodriguez Royo
-
Patent number: 7741372Abstract: There is disclosed a method for treating diseases and disorders involving T cell activation and HIV-infection using the p38 mitogen activated protein kinase (MAPK) signaling pathway as a target for intervention. There is further disclosed a use for guanylhydrazone-substituted compounds to treat diseases and disorders related to T cell activation and HIV-infection.Type: GrantFiled: July 16, 2003Date of Patent: June 22, 2010Assignee: Cytokine PharmaSciences, Inc.Inventors: Kevin J. Tracey, Pamela Cohen, Michael Bukrinsky, Helena Schmidtmayerova
-
Publication number: 20100152299Abstract: A process for preparing solid dosage forms that contain poorly compressible therapeutic compound. The process, for example, provides for the inventive use of an extruder, especially a twin screw extruder, to melt granulate a therapeutic compound(s) with a granulation excipient.Type: ApplicationFiled: May 8, 2006Publication date: June 17, 2010Inventors: Madhav Vasanthavada, Jay Lakshman, Wein-Qin Tong, Abu T. Serajuddin, Yatindra Joshi, James Kowalsi